Amsterdam Molecular Therapeutics B.V
AMSTERDAM, September 6, 2011 -
Gains US Patent Protection for Proprietary AAV Intellectual Property
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
AMSTERDAM, The Netherlands, August 25, 2011 -
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
AMSTERDAM, July 8, 2011 -
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, announced today that it has filed
a request for re-examination of the Marketing Authorisation
Application for Glybera with the European Medicines Agency.
AMSTERDAM, July 6, 2011 -
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today announced the appointment of
Dr.
AMSTERDAM, June 29, 2011 -
Data Presented at the
79thEuropean Atherosclerosis
Society Meeting
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today released data showing that
its gene therapy Glybera (alipogene tiparvovec) significantly
reduces the risk of pancreatitis in patients with Lipoprotein
Lipase Deficiency (LPLD).
More News
- Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
- Amsterdam Molecular Therapeutics Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi
- Data on Gene Therapy for LPLD Presented at ASGCT Annual Meeting
- AMT Provides Business Update for the First Quarter 2011
- Company to Present Updated Glybera Biomarker Data at American Society of Gene and Cell Therapy Annual Meeting
- AMT Receives Grant From Dutch Parents Organization for Duchenne Muscular Dystrophy Gene Therapy
- Amsterdam Molecular Therapeutics 2010 Annual Report
- Amsterdam Molecular Therapeutics Reports Full Year Results 2010
- /C O R R E C T I O N — Amsterdam Molecular Therapeutics B.V/
- AMT Receives EUR 1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as part of EU Consortium Grant
- AMT Gains Option to Acquire Commercial Rights to Sanfilippo B Gene Therapy Product
- Amsterdam Molecular Therapeutics Amends Amgen GDNF Gene License Agreement
- AMT Submits Responses to Day 120 Questions to EMA as Part of the Review Process for Glybera(R)
- AMT Provides Business Update for the Third Quarter 2010
- Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
- Amsterdam Molecular Therapeutics Successfully Raised EUR 14.3 m Through an Equity Issue
- Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and is not an offer for sale of securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.
- LPLchip(R) Rapidly and Precisely Detects Mutations Causing LPL Deficiency, a Cause of Acute Pancreatitis
- AMT's EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer
- Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
- AMT's Marketing Authorisation Application for Glybera(R) Progressing on Schedule
- Joseph Feczko (ex-Pfizer); Steven Holtzman (Infinity Pharmaceuticals); Franois Meyer (ex-Aventis) Slated to Reinforce Supervisory Board
- Gene Therapy Vector Successfully Delivers shRNA Into Liver Cells
- AMT Provides Business Update for the First Quarter 2010
- CFO Piers Morgan Appointed to Management Board
- Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
- Amsterdam Molecular Therapeutics Reports Full Year Results 2009
- EMA Starts Formal Review of Glybera(R) Dossier
- AMT Submits its Lead Product Glybera(R) Application for Marketing Authorisation Application to EMA
- AMT Receives Innovation Credit From Dutch Government for Duchenne Muscular Dystrophy
- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.
- AMT Announces Management Changes in Light of Refocused Strategy
- Glybera(R) Clinical Data Presented at Meeting of American Heart Association
- AMT Successful in Preclinical Treatment of DMD
- AMT Starts Development LPLChip(TM) With Progenika
